C-Reactive Protein and the Framingham Coronary Risk Score in Patients Newly Diagnosed With Intermittent Claudication

Objective: To investigate the relationship between serum C-reactive protein (CRP) levels and the calculated 10-year Framingham risk score (FRS) in patients newly diagnosed with intermittent claudication. Methods: Serum CRP levels were measured in 90 patients newly diagnosed with intermittent claudication over a 12-month period. In all, 76 patients (53 males [70%], mean age 63.3 ± 9.3) were included in the analysis. Results: Log-transformed CRP levels significantly correlated with total FRS ( r = .34, P = .002). Participants were divided into 4 groups according to log-CRP levels. Analysis of variance showed a statistically significant difference between the 4 groups in terms of mean FRS, P = .003. Post hoc comparisons indicated that group 1 was significantly different from group 4, P = .002. Analysis of covariance showed a significant difference between the 4 groups of log-CRP levels in terms of mean FRS, P = .008. Conclusion: There is an increased 10-year risk of coronary heart disease associated with increased plasma concentration of CRP in patients newly diagnosed with intermittent claudication.

Download Full-text

MO477SERUM C-REACTIVE PROTEIN AND PROCALCITONIN LEVELS IN HEMODIALYSIS AND INTRADIALYTIC ALTERATIONS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfab090.0039 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

Makrouhi Sonikian ◽

Aggeliki Barbatsi ◽

Eugenia Karakou ◽

Theodoros Chiras ◽

Jacob Skarakis ◽

...

Keyword(s):

Healthy Subjects ◽

Control Group ◽

Healthy Controls ◽

C Reactive Protein ◽

Polysulfone Membrane ◽

Reactive Protein ◽

Markers Of Inflammation ◽

Dialysate Flow Rate ◽

Significant Difference ◽

Serum Crp

Abstract Introduction C-reactive protein (CRP) and procalcitonin (PCT) are widely used as markers of inflammation and infection in general population and in chronic hemodialysis (HD) as well. However, in dialysis (D) patients, serum CRP and PCT levels may be elevated even in the absence of inflammatory or infectious disease and diagnostic process is a challenge in such cases. We studied HD patients' laboratory profile concerning CRP and PCT. Subjects and Methods We studied 25 stable HD patients, M/F=22/3, aged 68(44-89) years, dialyzed thrice weekly for 55(6-274) months with a dialysate flow rate of 700 ml/min, with a residual daily diuresis less than 200 ml, Kt/V values of 1,44±0,3 and no signs of infection. Patients were classified in two groups. Group A included 10 patients on pre-dilution online hemodiafiltration (HDF). Group B consisted of 15 patients on conventional HD with low-flux polysulfone membrane. Twenty healthy subjects formed a control group C. Serum CRP and PCT levels were measured in duplicate in A and B groups before and at the end of mid-week dialysis sessions and also in C group. Results Pre-D serum CRP values in the total of patients were higher than those in healthy controls (10,89±19,29 vs 2,54±1,28 mg/L-p=0,004). Compared with group C, pre-D CRP values were higher only in B group (15,98±24,54 mg/L-p=0,001) but not in A group (4,09±3,33 mg/L-p=NS). There was a significant difference in pre-D serum CRP values between A and B groups (p=0,028). At the end of D session serum CRP values showed a tendency to increase in both groups A (5,16±4,81 mg/L) and B (17,00±27,00 mg/L) but differences were not significant. Pre-D serum PCT values in the total of patients were higher than those in healthy controls (0,82±0,9 vs 0,29±0,55 ng/ml-p<0,001). Compared with group C, pre-D PCT values were higher in both A group (0,52±0,15 ng/ml-p<0,001) and B group (1,01±1,13 ng/ml-p=0,006). There was no significant difference in pre-D serum PCT values between A and B groups (p=0,261). At the end of D session serum PCT values decreased in A group (0,32±0,11 ng/ml-p<0,001) and increased in B group (1,12±1,21 ng/ml-p=0,014). Conclusions In patients on both conventional low-flux HD and online HDF pre-D serum CRP and PCT levels were higher than those in healthy subjects. Dialysis modality and membrane flux did not affect post-D serum CRP values, but post-PCT values decreased in online HDF. PCT usefulness might be limited in dialysis with high-flux membranes. Cut-off values have to be established for both markers to eliminate confusion in diagnosis of inflammatory and infectious diseases in hemodialyzed patients.

Download Full-text

Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index

Annals of the Rheumatic Diseases ◽

10.1136/ard.2009.125260 ◽

2010 ◽

Vol 69 (11) ◽

pp. 1976-1982 ◽

Cited By ~ 46

Author(s):

Hanneke J M Kerkhof ◽

Sita M A Bierma-Zeinstra ◽

Martha C Castano-Betancourt ◽

Moniek P de Maat ◽

Albert Hofman ◽

...

Keyword(s):

Systematic Review ◽

Body Mass Index ◽

Genetic Variation ◽

Body Mass ◽

Analysis Of Covariance ◽

C Reactive Protein ◽

Knee Oa ◽

Reactive Protein ◽

Serum Crp ◽

The Relationship

ObjectiveTo study the relationship between serum C reactive protein (CRP) levels, genetic variation in the CRP gene and the prevalence, incidence and progression of radiographic osteoarthritis (ROA) in the Rotterdam Study-I (RS-I). A systematic review of studies assessing the relationship between osteoarthritis (OA) and CRP levels was also performed.MethodsThe association between CRP levels and genetic variation in the CRP gene and ROA was examined in 861 patients with hand OA, 718 with knee OA, 349 with hip OA and 2806 controls in the RS-I using one-way analysis of covariance and logistic regression, respectively. PubMed was searched for articles published between January 1992 and August 2009 assessing the relationship between CRP levels and OA.ResultsIn RS-I the prevalence of knee OA, but not hip OA or hand OA, was associated with 14% higher serum CRP levels compared with controls (p=0.001). This association disappeared after adjustment for age and especially body mass index (BMI) (p=0.33). Genetic variation of the CRP gene was not consistently associated with the prevalence, incidence or progression of OA within RS-I. The systematic review included 18 studies (including RS-I) on serum CRP levels and the prevalence, incidence or progression of OA. Consistently higher crude CRP levels were found in cases of prevalent knee OA compared with controls. No association was observed between serum CRP levels and the prevalence of knee OA following adjustment for BMI (n=3 studies, meta-analysis p value=0.61).ConclusionThere is no evidence of association between serum CRP levels or genetic variation in the CRP gene with the prevalence, incidence or progression of OA independent of BMI.

Download Full-text

The Impact of Hyperbaric Oxygen Therapy on Serum C-Reactive Protein Levels, Osteoprotegerin Expression, and Osteoclast Numbers in Induced-Periodontitis Diabetic Rats

European Journal of Dentistry ◽

10.1055/s-0040-1712072 ◽

2020 ◽

Vol 14 (03) ◽

pp. 404-409

Author(s):

Dian Mulawarmanti ◽

Kristanti Parisihni ◽

Widyastuti Widyastuti

Keyword(s):

Hyperbaric Oxygen ◽

Hyperbaric Oxygen Therapy ◽

Oxygen Therapy ◽

Diabetic Rats ◽

Diabetic Group ◽

C Reactive Protein ◽

Reactive Protein ◽

Significant Difference ◽

Serum Crp ◽

The Impact

Abstract Objectives This study aimed to examine the impact of hyperbaric oxygen therapy (HBOT) on serum C-reactive protein (CRP) levels, osteoclast numbers, and osteoprotegerin (OPG) expression in periodontitis-induced diabetic rats Materials and Methods This study constituted an in vivo laboratory-based experiment incorporating a posttest only control group design. Thirty male Wistar rats were divided into three groups of research subjects: a healthy group (K0), periodontitis-induced diabetic group (K1), and periodontitis-induced diabetic group treated with HBOT for 7 days (K2). After treatment, the subjects were sacrificed to determine the level of serum CRP by the ELISA method. Immunohistochemical analysis was conducted to check the level of OPG expression, while a histological analysis was undertaken to quantify the number of osteoclasts. Statistical Analysis The data was analyzed using a one-way ANOVA and Least Significant Difference (LSD) test on which a result of p < 0.05 was considered statistically significant. Results HBOT appreciably decreased serum CRP levels, significantly enhancing OPG expression in periodontitis-induced diabetic (p < 0.05) and decreasing the number of osteoclasts in -periodontitis-induced diabetic (p > 0.05). Conclusion HBOT reduced the serum CRP level, increased OPG expression, and decreased osteoclast numbers in periodontitis-induced diabetic rats.

Download Full-text

Abstract: P1244 HIGHLY SENSITIVE C-REACTIVE PROTEIN AND THE FRAMINGHAM RISK SCORE ARE ASSOCIATED WITH CORONARY DISEASE SEVERITY IN PATIENTS WITH METABOLIC SYNDROME

Atherosclerosis Supplements ◽

10.1016/s1567-5688(09)71261-9 ◽

2009 ◽

Vol 10 (2) ◽

pp. e1299

Author(s):

C Monteiro ◽

M Izar ◽

S Brandao ◽

S Fischer ◽

S Barros ◽

...

Keyword(s):

Metabolic Syndrome ◽

Disease Severity ◽

Coronary Disease ◽

Risk Score ◽

Framingham Risk Score ◽

C Reactive Protein ◽

Reactive Protein ◽

Framingham Risk ◽

Highly Sensitive

Download Full-text

Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites

Digestive Diseases ◽

10.1159/000494438 ◽

2019 ◽

Vol 37 (3) ◽

pp. 239-246 ◽

Cited By ~ 5

Author(s):

Yohei Kida

Keyword(s):

Therapeutic Response ◽

Positive Response ◽

Body Weight Loss ◽

Newly Diagnosed ◽

C Reactive Protein ◽

Reactive Protein ◽

Significant Difference ◽

V2 Receptor ◽

Vasopressin V2 Receptor Antagonist ◽

Cirrhotic Patients

Aims: Ascites is one of the major complications in advanced cirrhotic patients. Tolvaptan is a non-peptide orally available arginine vasopressin V2 receptor antagonist. We investigated and found that tolvaptan therapy improved the prognosis and predictive factor of cirrhotic patients with ascites. Methods: Overall, 99 patients with newly diagnosed ascites with cirrhosis were enrolled. No patients had intrahepatic malignancy. The patients were divided into 2 groups based on tolvaptan therapy: 86 patients treated with tolvaptan (tolvaptan-group) and 13 patients treated without tolvaptan (non-tolvaptan-group). Tolvaptan-responder was defined as body weight loss of ≥1.5 kg/week after administering tolvaptan. Results: Tolvaptan therapy was effective in 61.6% of cirrhotic patients. There was a significant difference in the overall survival (OS) between the tolvaptan-responder-group and the other groups (p < 0.001). Male (HR 5.05; p = 0.01), tolvaptan responder (HR 0.21; p = 0.02), and dosage of furosemide < 40 mg/day (HR 0.17; p = 0.01) were factors that were independently associated with the OS. The multivariate analysis revealed that C-reactive protein < 0.9 mg/dL (HR 0.07; p = 0.001), and furosemide dosage < 40 mg/day (HR 0.09; p = 0.003) were independently associated with the tolvaptan response. Conclusion: Therapeutic response to tolvaptan was associated with longer survival in cirrhosis patients complicated with ascites. These preliminary findings warrant validation and further exploration.

Download Full-text